WX390 not checked

Shanghai Jiatan Pharmatech Co., Ltd · WXFL10030390

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
6 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive WX390 continuous oral dosing (1.1 mg once a day) and Toripalimab fixed dose (240mg, intravenous, Day 1, every 3 weeks).”In the company’s words, NCT07392060 on ClinicalTrials.gov
Tested for
Cervical Cancer Metastatic, Gastric Type Adenocarcinoma (GAS) With STK11 Mutation, Solid Tumor
Main trialPhase 3
“This is a Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study to evaluate the efficacy of WX390 in combination with toripalimab versus investigator's choice of therapy in patients with recurrent or metastatic cervical cancer who have failed at least one prior platinum-based systemic therapy, as assessed by overall survival (OS).”In the company’s words, NCT07392060 on ClinicalTrials.gov
Other names
WXFL10030390

Other drugs for Solid Tumor

All 2440 drugs for Solid Tumor

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 30 Sep 2029 A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment
Phase 2Recruiting 12 Dec 2025 A Study of WX390 Combined With Toripalimab in Patients With Advanced Gastric-type Endocervical Adenocarcinoma With STK11 Mutations
Phase 1/2Recruiting 9 Nov 2025 A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Phase 2Unknown 12 Jun 2025 A Study of WX390 in Patients With Advanced Solid Tumors
Phase 1/2Completed 3 Jan 2023 A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations
Phase 1Completed 25 Jul 2020 A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow WX390

Following is part of Solo: you see every change to WX390 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in